CDA | Evidence Driven
CDA | Evidence Driven

Votrient for metastatic renal cell carcinoma - Resubmission - Details

Details

Files
Generic Name:
Pazopanib hydrochloride
Project Status:
Complete
Therapeutic Area:
Metastatic Renal Cell Carcinoma
Manufacturer:
GlaxoSmithKline Inc.
Brand Name:
Votrient
Project Line:
Reimbursement Review
Project Number:
PC0022-000
Performance Metric:
N/A — Predated performance metrics
Strength:
200 mg
Tumour Type:
Genitourinary
Indications:
Metastatic Renal Cell Carcinoma
Funding Request:
First-line therapy in patients with metastatic renal cell (clear cell) carcinoma with good performance status (ECOG 0-1)
Review Status:
Complete
Sponsor:
GlaxoSmithKline Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
pERC Meeting:
Final Recommendation Issued:

The manufacturer, GlaxoSmithKline Inc. has resubmitted to pCODR for the Pazopanib Hydrochloride (Votrient) submission. Please see the Pazopanib hydrochloride (Votrient) for Metastatic Renal Cell Carcinoma Details page for information pertaining to the original submission.

Files

Provincial Funding Summary View PDF
Pazopanib (Votrient) for mRCC Resubmission - pERC Final Recommendation Final Recommendation August 29, 2013 View PDF
Pazopanib (Votrient) Resub - Un-redacted Final Clinical Guidance Report Guidance Reports August 29, 2013 View PDF
Pazopanib (Votrient) for mRCC Resubmission - Final Economic Guidance Report Guidance Reports August 29, 2013 View PDF
Pazopanib (Votrient) for mRCC Resubmission - pERC Initial Recommendation Initial Recommendation July 5, 2013 View PDF
Pazopanib (Votrient) for mRCC Resubmission - PAG Feedback on Initial Recommendation Feedback August 29, 2013 View PDF
Pazopanib (Votrient) for mRCC Resubmission - Manufacturer (GlaxoSmithKline) Feedback on Initial Recommendation Feedback August 29, 2013 View PDF
Pazopanib (Votrient) for mRCC Resubmission - Patient Advocacy Feedback on Initial Recommendation (KCC) Feedback August 29, 2013 View PDF
Pazopanib (Votrient) for mRCC Resubmission - Patient Advocacy Group (KCC) COI Declarations Feedback August 29, 2013 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : September 17, 2013